Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin on cardiovascular and non-cardiovascular causes of death. Methods and results: DAPA-CKD was an international, randomized, placebo-controlled trial with a median of 2.4 years of follow-up. Eligible participants were adult patients with CKD, defined as a urinary albumin-to-creatinine ratio (UACR) 200–5000 mg/g and an estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m2. All-cause mortality was a key secondary endpoint. Cardiovascular and non-cardiovascular death was adjudicated by an independent clinical events committee. The DAPA-CKD trial randomized participants to dapagliflozin 10 mg/day (n = 2152) or placebo (n = 2152). The mean age was 62 years, 33% were women, the mean eGFR was 43.1 mL/min/1.73 m2, and the median UACR was 949 mg/g. During follow-up, 247 (5.7%) patients died, of whom 91 (36.8%) died due to cardiovascular causes, 102 (41.3%) due to non-cardiovascular causes, and in 54 (21.9%) patients, the cause of death was undetermined. The relative risk reduction for all-cause mortality with dapagliflozin (31%, hazard ratio [HR] [95% confidence interval (CI)] 0.69 [0.53, 0.88]; P = 0.003) was consistent across pre-specified subgroups. The effect on all-cause mortality was driven largely by a 46% relative risk reduction of non-cardiovascular death (HR [95% CI] 0.54 [0.36, 0.82]). Deaths due to infections and malignancies were the most frequently occurring causes of non-cardiovascular deaths and were reduced with dapagliflozin vs. placebo. Conclusion: In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationBaigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Self-citationMosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684
Self-citationPalmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395 · cited 9×
“19 There were also differences in the design of the trials, such as the possibility to continue study medication when dialysis was initiated in DAPA-CKD.”
InfluentialSelf-citationRenoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393 · cited 1×
“8,9 These findings have led to the hypothesis that SGLT2 inhibitors may also preserve kidney function in patients with CKD without Type 2 diabetes.”
Self-citationCanagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361 · cited 1×
“8,9 These findings have led to the hypothesis that SGLT2 inhibitors may also preserve kidney function in patients with CKD without Type 2 diabetes.”
Self-citationProblems With Proper Completion and Accuracy of the Cause-of-Death Statement
Sehdev, A. E. S., & Hutchins, G. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.2.277 · Cited by 342
Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018010103 · Cited by 209
Self-citationScafoglio, C. R., Villegas, B., Abdelhady, G., Bailey, S. T., Liu, J., Shirali, A. S., Wallace, W. D., Magyar, C. E., Grogan, T. R., Elashoff, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat5933 · Cited by 176 · cited 1×
“In addition, SGLT2 inhibition with dapagliflozin and canagliflozin reduced tumour growth and prolonged survival in a mouse model and patient-derived xenografts of lung adenocarcinomas.(24) Dapagliflozin also inhibited cell growth in renal and hepatocellular carcinoma cell lines by inducing cell cycle arrest and enhanc…”
Cited by
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationEvans, M., Lewis, R. D., Morgan, A. R., Whyte, M. B., Hanif, W., Bain, S. C., Davies, S., Dashora, U., Yousef, Z., Patel, D. C., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-021-01927-z · Cited by 310
Self-citationKosiborod, M. N., Esterline, R., Furtado, R. H. M., Oscarsson, J., Gasparyan, S. B., Koch, G. G., Martinez, F., Mukhtar, O., Verma, S., Chopra, V., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00180-7 · Cited by 243
Self-citationZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
Self-citation
Metadata
- Authors
- Heerspink, H. J. L., Sjöström, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., McMurray, J. J. V., Rossing, P., Correa-Rotter, R., Kurlyandskaya, R., Stefansson, B. V., Toto, R. D., Langkilde, A. M., Wheeler, D. C., for the DAPA-CKD Trial Committees and Investigators, Heerspink, H. J. L., Wheeler, D. C., Chertow, G., Correa-Rotter, R., Greene, T., Fan Hou, F., McMurray, J., Rossing, P., Toto, R., Stefansson, B., Maria Langkilde., A., Maffei, L. E., Raffaele, P., Solis, S. E., Arias, C. A., Aizenberg, D., Luquez, C., Zaidman, C., Cluigt, N., Mayer, M., Alvarisqueta, A., Wassermann, A., Maldonado, R., Bittar, J., Maurich, M., Gaite, L. E., Garcia, N., Sivak, L., Ramallo, P. O., Santos, J. C., Garcia Duran, R., Oddino, J. A., Maranon, A., Maia, L. N., D Avila, D., Barros, E. J. G., Vidotti, M. H., Panarotto, D., Noronha, I. D. L., Turatti, L. A. A., Deboni, L., Canziani, M. E., Riella, M. C., Bacci, M. R., Paschoalin, R. P., Franco, R. J., Goldani, J. C., St-Amour, E., Steele, A. W., Goldenberg, R., Pandeya, S., Bajaj, H., Cherney, D., Kaiser, S. M., Conway, J. R., Chow, S. S., Bailey, G., Lafrance, J., Winterstein, J., Cournoyer, S., Gaudet, D., Madore, F., Houlden, R. L., Dowell, A., Langlois, M., Muirhead, N., Khandwala, H., Levin, A., Hou, F., Xue, Y., Zuo, L., Hao, C., Ni, Z., Xing, C., Chen, N., Dong, Y., Zhou, R., Xiao, X., Zou, Y., Wang, C., Liu, B., Chen, Q., Lin, M., Luo, Q., Zhang, D., Wang, J., Chen, M., Wang, X., Zhong, A., Dong, J., Zhu, C., Yan, T., Luo, P., Ren, Y., Pai, P., Li, D., Zhang, R., Zhang, J., Xu, M., Zhuang, Y., Kong, Y., Yao, X., Peng, X., Persson, F. I., Hansen, T. K., Borg, R., Pedersen Bjergaard, U., Hansen, D., Hornum, M., Haller, H., Klausmann, G., Tschope, D., Kruger, T., Gross, P., Hugo, C., Obermuller, N., Rose, L., Mertens, P., Zeller-Stefan, H., Fritsche, A., Renders, L., Muller, J., Budde, K., Schroppel, B., Wittmann, I., Voros, P., Dudas, M., Tabak, G. A., Kirschner, R., Letoha, A., Balku, I., Hermanyi, Z., Zakar, G., Mezei, I., Nagy, G. G., Lippai, J., Nemeth, A., Khullar, D., Gowdaiah, P. K., Fernando Mervin, E., Rao, V. A., Dewan, D., Maddi, V. S. K., Vyawahare, M. S., Pulichikkat, R. K., Sonkar, S. K., Gupta, V. K., Agarwal, S., Asirvatham, A. J., Ignatius, A., Chaubey, S., Melemadathil, S., Alva, H., Kadam, Y., Shimizu, H., Sueyoshi, A., Takeoka, H., Abe, Y., Imai, T., Onishi, Y., Fujita, Y., Tokita, Y., Makita, Y., Idogaki, A., Koyama, R., Kikuchi, H., Kashihara, N., Hayashi, T., Ando, Y., Tanaka, T., Shimizu, M., Hidaka, S., Gohda, T., Tamura, K., Abe, M., Kamijo, Y., Imasawa, T., Takahashi, Y., Nakayama, M., Tomita, M., Hirano, F., Nakayama, M., Fukushima, Y., Kiyosue, A., Kurioka, S., Imai, E., Kitagawa, K., Waki, M., Wada, J., Uehara, K., Iwatani, H., Ota, K., Shibazaki, S., Tamura, K., Katayama, K., Narita, I., Iinuma, M., Matsueda, S., Sasaki, S., Yokochi, A., Tsukamoto, T., Yoshimura, T., Kang, S., Lee, S., Lim, C. S., Chin, H., Joo, K. W., Han, S. Y., Chang, T. I., Park, S., Park, H., Park, C. W., Han, B. G., Cha, D. R., Yoon, S. A., Kim, W., Kim, S. W., Ryu, D., Correa Rotter, R., Irizar Santana, S. S., Hernandez Llamas, G., Valdez Ortiz, R., Secchi Nicolas, N. C., Gonzalez Galvez, G., Lazcano Soto, J. R., Bochicchio Riccardelli, T., Bayram Llamas, E. A., Ramos Ibarra, D. R., Melo, M. G. S., Gonzalez Gonzalez, J. G., Sanchez Mijangos, J. H., Madero Robalo, M., Garcia Castillo, A., Manrique, H. A., Farfan, J. C., Vargas, R., Valdivia, A., Dextre, A., Escudero, E., Calderon Ticona, J. R., Gonzales, L., Villena, J., Leon, L., Molina, G., Saavedra, A., Garrido, E., Arbanil, H., Vargas Marquez, S., Rodriguez, J., Isidto, R., Villaflor, A. J., Gumba, M. A., Tirador, L., Comia, R. S., Sy, R. A., Guanzon, M. L. V. V., Aquitania, G., De Asis, N. C., Silva, A. A., Lim, M. E., Danguilan, R. A., Nowicki, M., Rudzki, H., Landa, K., Kucharczyk-Bauman, I., Gogola-Migdal, B., Golski, M., Olech-Cudzik, A., Stompor, T., Szczepanik, T., Miklaszewicz, B., Sciborski, R., Kuzniewski, M., Ciechanowski, K., Wronska, D., Klatko, W., Mazur, S., Popenda, G., Myslicki, M., Bolieva, L. Z., Berns, S., Galyavich, A., Abissova, T., Karpova, I., Platonov, D., Koziolova, N., Kvitkova, L., Nilk, R., Medina, T., Rebrov, A., Rossovskaya, M., Sinitsina, I., Vishneva, E., Zagidullin, N., Novikova, T., Krasnopeeva, N., Magnitskaya, O., Antropenko, N., Batiushin, M., Escudero Quesada, V, Barrios Barrea, C., Espinel Garauz, E., Cruzado Garrit, J. M., Morales Portillo, C., Gorriz Teruel, J. L., Cigarran Guldris, S., Praga Terente, M., Robles Perez-Monteoliva, N. R., Infanta Cristina, H., Tinahones Madueno, F. J., Soto Gonzalez, A., Diaz Rodriguez, C., Furuland, H., Saeed, A., Dreja, K., Spaak, J., Bruchfeld, A., Kolesnyk, M., Levchenko, O., Pyvovarova, N., Stus, V, Doretskyy, V, Korobova, N., Horoshko, O., Katerenchuk, I., Mostovoy, Y. M., Orynchak, M., Legun, O., Dudar, I., Bilchenko, O., Andreychyn, S., Levchenko, A., Zub, L., Tereshchenko, N., Topchii, I., Ostapenko, T., Bezuglova, S., Kopytsya, M., Turenko, O., Mark, P., Barratt, J., Bhandari, S., Fraser, D., Kalra, P., Kon, S. P., Mccafferty, K., Mikhail, A., Kon, S. P., Alvarado, O. P., Anderson, R., Andrawis, N. S., Arif, A., Benjamin, S. A., Bueso, G., Busch, R. S., Carr, K. W., Carr, K. W., Crawford, P., Daboul, N., De La Calle, G. M., Delgado, B., Earl, J., El-Shahawy, M. A., Graf, R. J., Greenwood, G., Guevara, A., Wendland, E. M., Mayfield, R. K., Montero, M., Morin, D. J., Narayan, P., Numrungroad, V, Reddy, A. C., Reddy, R., Samson, M. B., Trejo, R., Butcher, M. B., Wise, J. K., Zemel, L. R., Raikhel, M., Weinstein, D., Hernandez, P., Wynne, A., Khan, B. V., Sterba, G. A., Jamal, A., Ross, D., Rovner, S. F., Tan, A., Ovalle, F., Patel, R. J., Talano, J., Patel, D. R., Burgner, A., Aslam, N., Elliott, M., Goral, S., Jovanovich, A., Umanath, K., Waguespack, D., Weiner, D., Yu, M., Schneider, L., Le, T., D, T., Nguyen, N., Nguyen, H., Nguyen, D., Nguyen, V, Do, T., Chu, P., Ta, D., Tran, N., Nguyen, D., Pfeffer, M. A., Pocock, S., Swedberg, K., Rouleau, J. L., Chaturvedi, N., Ivanovich, P., Levey, A. S., Held, C., Christersson, C., Mann, J., & Varenhorst, C.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-31
- Volume
- 42
- Issue
- 13
- Pages
- 1216-1227
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W3150973581
- Cited by
- 121
- References
- 10
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehab094
- The paper
- Heerspink, H. J. L., Sjöström, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., McMurray, J. J. V., Rossing, P., Correa-Rotter, R., Kurlyandskaya, R., Stefansson, B. V., Toto, R. D., Langkilde, A. M., Wheeler, D. C., for the DAPA-CKD Trial Committees and Investigators, Heerspink, H. J. L., Wheeler, D. C., Chertow, G., Correa-Rotter, R., . . . Varenhorst, C. (2021). Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab094
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.